Processa Pharmaceuticals, Inc. Prepaid Expense, Noncurrent
Processa Pharmaceuticals, Inc. (PCSA) had Prepaid Expense, Noncurrent of $993.70 thousand as of 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:PrepaidExpenseNoncurrent · last filed 2026-08-14
- 2026-03-31: Prepaid Expense, Noncurrent $993.70K.
- 2025-12-31: Prepaid Expense, Noncurrent $993.70K.
- 2025-09-30: Prepaid Expense, Noncurrent $993.70K.
- 2025-06-30: Prepaid Expense, Noncurrent $993.70K.
| Period end | Prepaid Expense, Noncurrent |
|---|---|
| 2026-03-31 | $993.70K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $993.70K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $993.70K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $993.70K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $993.70K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.27M 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |